Detalhe da pesquisa
1.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Lancet
; 403(10424): 379-390, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109916
2.
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing Triggers.
Am J Nephrol
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423000
3.
Renal Autologous Cell Therapy in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis.
Blood Purif
; 52(2): 114-121, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36599315
4.
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design.
Am J Nephrol
; 53(1): 50-58, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034024
5.
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.
Am J Nephrol
; 52(3): 180-189, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789284
6.
Poly-ADP ribose polymerase-14 limits severity of allergic skin disease.
Immunology
; 152(3): 451-461, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28653395
7.
Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.
Am J Nephrol
; 40(6): 535-45, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25572630
8.
A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
Hemodial Int
; 28(1): 59-71, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875459
9.
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.
Kidney360
; 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38323855
10.
Challenges of Conducting Clinical Trials during the SARS-CoV-2 Pandemic: The ASCEND Global Program Experience.
Kidney360
; 3(4): 728-733, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35721625
11.
Effects of Bardoxolone Methyl in Alport Syndrome.
Clin J Am Soc Nephrol
; 17(12): 1763-1774, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411058
12.
Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
Kidney360
; 2(10): 1600-1610, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35372979
13.
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Cardiorenal Med
; 9(5): 316-325, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31170712
14.
Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study.
Kidney360
; 4(11): 1580-1589, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37853560
15.
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
J Diabetes Complications
; 32(12): 1113-1117, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30318163
16.
Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice.
Life Sci
; 74(5): 543-52, 2003 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-14623025
17.
Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.
Nephrol Dial Transplant
; 20(6): 1232-7, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15840675